Topics in Cancer Genetics Research

Given the increasing frequency of Hematologic Malignancy, especially in an aging population, as well as the complexities of individual clinic presentation, there is a need to provide an opportunity for Oncologists, Hematologists and Oncology Nurses to engage in a thoughtful examination and discussion with experts in various hematologic cancers. There is also emerging data about the biology of these cancers that underlies modern optimal management of patients with these disorders. The expansion of patient care options in nearly all of these disorders make decision making more complex. This two and a half day symposium has been designed by experts in the field of hematologic malignancies and affords the conferee specialized educational tracks for both physicians and nurses providing the opportunity to learn about the most recent advances in the treatment of bone marrow transplant, multiple myeloma, lymphoma and leukemia. Updates on improved curative and palliative treatments and evolving molecular and immunologically-based system therapies, as well as important, completed or ongoing clinical trials, will be profiled and discussed.

EVENT DETAILS AND REGISTRATION

Date:March 11, 2016

Time: 11:30 AM - 12:30 PM (PT)

Location:Modular #173

Event Is:At the end of this continuing medical education activity, participants should be able to:

  • Review the role and timing of hem cell transplant in the management of younger and older patients
  • Provide an update of new molecular and immunological treatments being developed for these diseases
  • Discuss the rationale for new targeted diagnositc therapeutic strategies for lymphoma, myeloma and leukemia
  • Summarize the evolving therapeutic strategies in the treatment of hematologic malignanacies
  • Integrate best practices for prevention, detection and management of side effects related to current therapies

ADDITIONAL DETAILS:

Objectives:

At the end of this continuing medical education activity, participants should be able to:
  • Review the role and timing of hem cell transplant in the management of younger and older patients
  • Provide an update of new molecular and immunological treatments being developed for these diseases
  • Discuss the rationale for new targeted diagnositc therapeutic strategies for lymphoma, myeloma and leukemia
  • Summarize the evolving therapeutic strategies in the treatment of hematologic malignanacies
  • Integrate best practices for prevention, detection and management of side effects related to current therapies

Who should attend:

Clinical Cancer Genetics Staff, Medical Oncology and Hematology

CME credits:1.0 AMA/PRA Category 1 Credit™ The City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. City of Hope designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.TM

R.S.V.P.: Please Contact Debbie Niemi-Escalera Ext. 64008

Contact:

Debbie Niemi-Escalera